DK1106178T3 - Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose - Google Patents

Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose

Info

Publication number
DK1106178T3
DK1106178T3 DK98936715T DK98936715T DK1106178T3 DK 1106178 T3 DK1106178 T3 DK 1106178T3 DK 98936715 T DK98936715 T DK 98936715T DK 98936715 T DK98936715 T DK 98936715T DK 1106178 T3 DK1106178 T3 DK 1106178T3
Authority
DK
Denmark
Prior art keywords
ibudilast
treatment
medicament
manufacture
disseminated sclerosis
Prior art date
Application number
DK98936715T
Other languages
Danish (da)
English (en)
Inventor
Saburo Sakoda
Original Assignee
Kyorin Seiyaku Kk
Saburo Sakoda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk, Saburo Sakoda filed Critical Kyorin Seiyaku Kk
Application granted granted Critical
Publication of DK1106178T3 publication Critical patent/DK1106178T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicinal Preparation (AREA)
DK98936715T 1998-08-10 1998-08-10 Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose DK1106178T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1998/003548 WO2000009127A1 (fr) 1998-08-10 1998-08-10 Traitements contre la sclerose en plaques

Publications (1)

Publication Number Publication Date
DK1106178T3 true DK1106178T3 (da) 2005-02-28

Family

ID=14208769

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98936715T DK1106178T3 (da) 1998-08-10 1998-08-10 Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose

Country Status (11)

Country Link
US (1) US6395747B1 (fr)
EP (1) EP1106178B1 (fr)
JP (1) JP4828003B2 (fr)
AT (1) ATE283047T1 (fr)
AU (1) AU8562198A (fr)
CA (1) CA2339934C (fr)
DE (1) DE69827853T2 (fr)
DK (1) DK1106178T3 (fr)
ES (1) ES2231998T3 (fr)
PT (1) PT1106178E (fr)
WO (1) WO2000009127A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302588A1 (en) 2002-12-03 2004-06-23 Kyorin Pharmaceutical Co., Ltd. Phosphodiesterase 10a inhibitors
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
US20060093578A1 (en) * 2004-11-04 2006-05-04 Kyorin Pharmaceutical Co., Ltd. Method and composition for treating multiple sclerosis
JP4954085B2 (ja) * 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
KR100780479B1 (ko) 2006-05-08 2007-11-28 윈셋파마 주식회사 이부딜라스트 함유 경구용 제제 및 이의 제조방법
WO2007142924A1 (fr) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast destiné à inhiber l'activité du facteur inhibiteur de la migration des macrophages (mif)
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
WO2008137012A1 (fr) * 2007-05-03 2008-11-13 Avigen, Inc. Utilisation d'un atténuateur glial destiné à prévenir des réponses de douleurs amplifiées provoquées par un amorçage glial
US8138201B2 (en) * 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2018119262A1 (fr) 2016-12-22 2018-06-28 Medicinova, Inc. Procédés de traitement d'un glioblastome multiforme à l'aide d'ibudilast
ES2959799T3 (es) * 2018-02-12 2024-02-28 Medicinova Inc Métodos para suprimir células supresoras de origen mieloide en pacientes
JP2021512921A (ja) 2018-02-12 2021-05-20 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
US20210145838A1 (en) * 2018-04-05 2021-05-20 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
WO2020076809A1 (fr) 2018-10-09 2020-04-16 Medicinova, Inc. Association d'ibudilast et d'interféron-bêta et méthodes d'utilisation associées
CN112804999B (zh) 2018-10-19 2024-03-15 美迪诺亚公司 通过异丁司特治疗眼科疾病/病症或损伤的方法
WO2020251748A1 (fr) * 2019-06-11 2020-12-17 Yale University Nouveau traitement du syndrome de wolfram
EP4034090A1 (fr) 2019-09-23 2022-08-03 MediciNova, Inc. Formulations orales d'ibudilast et méthodes d'utilisation de celles-ci
CA3174413A1 (fr) 2020-04-06 2021-10-14 Yuichi Iwaki Procedes de reduction du taux plasmatique d'un facteur d'inhibition de la de migration des macrophages chez des patients soignes par l'idubilast
WO2022164948A1 (fr) 2021-01-29 2022-08-04 Medicinova, Inc. Méthodes de traitement d'une exposition à des gaz chimiques
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
CA3231869A1 (fr) 2021-09-21 2023-03-30 Medicinova, Inc. Ibudilast en polytherapie destine a etre utilise dans le traitement du glioblastome
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
CN118973574A (zh) 2022-02-01 2024-11-15 美迪诺亚公司 异丁司特治疗新冠肺炎后遗症的用途
US20240016729A1 (en) 2022-07-13 2024-01-18 Medicinova, Inc. Injectable formulations of ibudilast
WO2026060180A1 (fr) 2024-09-11 2026-03-19 Medicinova, Inc. Formulations d'ibudilast à libération modifiée

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
WO1996006843A1 (fr) * 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive de naphtyridine et composition medicinale a base de ce derive

Also Published As

Publication number Publication date
DE69827853T2 (de) 2005-12-08
PT1106178E (pt) 2005-02-28
EP1106178A4 (fr) 2001-11-21
CA2339934C (fr) 2008-06-03
JP4828003B2 (ja) 2011-11-30
ES2231998T3 (es) 2005-05-16
CA2339934A1 (fr) 2000-02-24
DE69827853D1 (de) 2004-12-30
US6395747B1 (en) 2002-05-28
ATE283047T1 (de) 2004-12-15
EP1106178A1 (fr) 2001-06-13
EP1106178B1 (fr) 2004-11-24
WO2000009127A1 (fr) 2000-02-24
AU8562198A (en) 2000-03-06

Similar Documents

Publication Publication Date Title
DK1106178T3 (da) Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose
ATE359077T1 (de) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DK0594607T3 (da) Forøgelse af nedreguleringen af autoimmune sygdomme ved oral eller enteral indgivelse af autoantigener
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
NO870241L (no) Hypoglykemiske tiazolidindioner.
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
FR2444671A1 (fr) Nouvelles quinazolinones, leur preparation et medicament contenant ces substances
DK0845984T3 (da) Anvendelse af aminoadamantan-forbindelser som immunregulatorer
IT1318667B1 (it) Medicamento antinfiammatorio.
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
YU37001A (sh) Kombinacija lekova analgetika
FR2392990A1 (fr) Medicament a base d'un compose heterocyclique bicyclique condense
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
BR9708922A (pt) Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso
RU2002132883A (ru) Новые полициклические инданилимидазолы, обладающие альфа2 адренергической активностью
KR910002818A (ko) 4,5,6,7-사치환된 벤즈옥사졸론
DK1395289T3 (da) Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist
IT1296613B1 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.
NO20013480L (no) Legemiddel for torr hud
FR2409752A1 (fr) Medicament agissant notamment sur le systeme nerveux central a base d'aryl-2 allophanates d'ethyle